2022 World Conference on Lung Cancer (ePosters)-EP08.01-082. Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study

EP08.01-082. Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study

Back to course

Pdf Summary

A prospective study was conducted to assess therapeutic resistance and clonal evolution in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). The study aimed to establish and validate a model for predicting treatment outcomes and explore the underlying resistance mechanisms. EGFR and ALK negative advanced NSCLC patients receiving first-line ICIs were recruited, and pre-treatment circulating tumor DNA (ctDNA), peripheral blood mononuclear cells (PBMC), and on-treatment ctDNA were collected and analyzed using panel sequencing and RNA sequencing. These data, along with pre-treatment ctDNA and immune features, were integrated using a multiparameter Bayesian framework. The preliminary results of the study demonstrated the high accuracy of the integrated model in predicting clinical outcomes. The study is ongoing, with more patients and data expected to optimize the prediction model and analyze the potential mechanism of early resistance to ICIs in advanced NSCLC patients. This research provides insights into personalized treatment strategies for NSCLC patients receiving ICIs and may contribute to improving patient outcomes.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

prospective study

therapeutic resistance

clonal evolution

non-small cell lung cancer

immune checkpoint inhibitors

treatment outcomes

circulating tumor DNA

RNA sequencing

integrated model

personalized treatment strategies